Kukoamine A

Synonyms: 地骨皮甲素
Kukoamine A 是一种具有口服活性且可穿透血脑屏障的精胺类生物碱,存在于宁夏枸杞(Lycium chinense,L. chinense)Miller 的根皮中,可抑制纯化的簇生锥虫锥虫硫醇还原酶和大豆脂氧合酶(lipoxygenase),并激活 μ-阿片(μ-opioid)受体,从而抑制癌细胞增殖、迁移和侵袭,引起 G0/G1 期细胞周期阻滞并诱导细胞凋亡(apoptosis),同时具有神经保护作用并可诱导自噬(autophagy),还可抑制 LPS(MS-X54539)诱导的 NO、ROS、PGE2、TNF-α、IL-1β、IL-6 产生以及 COX-2 活性,并通过下调 Srebp-1c 逆转棕榈酸诱导的胰岛素抵抗、脂质蓄积和氧化应激,因此可用于癌症、感染、炎症、代谢性疾病和神经系统疾病(例如胶质母细胞瘤和帕金森病)的研究。
产品编号: MS-W44155 纯度: 99.88% CAS No.: 75288-96-9 分子式: C28H42N4O6 分子量: 530.66
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Kukoamine A 是一种具有口服活性且可穿透血脑屏障的精胺类生物碱,存在于宁夏枸杞(Lycium chinense,L. chinense)Miller 的根皮中,可抑制纯化的簇生锥虫锥虫硫醇还原酶和大豆脂氧合酶(lipoxygenase),并激活 μ-阿片(μ-opioid)受体,从而抑制癌细胞增殖、迁移和侵袭,引起 G0/G1 期细胞周期阻滞并诱导细胞凋亡(apoptosis),同时具有神经保护作用并可诱导自噬(autophagy),还可抑制 LPS(MS-X54539)诱导的 NO、ROS、PGE2、TNF-α、IL-1β、IL-6 产生以及 COX-2 活性,并通过下调 Srebp-1c 逆转棕榈酸诱导的胰岛素抵抗、脂质蓄积和氧化应激,因此可用于癌症、感染、炎症、代谢性疾病和神经系统疾病(例如胶质母细胞瘤和帕金森病)的研究。

生物实验数据

生物活性 Kukoamine A is an orally active, blood-brain barrier-penetrating spermine alkaloid found in the root bark of Lycium chinense (L. chinense) Miller that inhibits purified Trypanosoma brucei brucei trypanothione reductase and soybean lipoxygenase and activates the μ-opioid receptor, thereby inhibiting cancer cell proliferation, migration, and invasion, inducing G0/G1 cell cycle arrest and apoptosis, exerting neuroprotective effects and inducing autophagy, inhibiting LPS (MS-X54539)-induced production of NO, ROS, PGE2, TNF-α, IL-1β, and IL-6 as well as COX-2 activity, and reversing palmitic acid-induced insulin resistance, lipid accumulation, and oxidative stress via downregulation of Srebp-1c, making it useful for research on cancer, infection, inflammation, metabolic diseases, and neurological diseases such as glioblastoma and Parkinson's disease.
IC50 & Target Trypanothione reductase:1.8 microM(Ki), LOX:9.5 microM
体外研究
(In Vitro)

Kukoamine A 作为混合型抑制剂可强效抑制纯化的 Crithidia fasciculata 锥虫硫醇还原酶,其 Ki 为 1.8 μM、对酶-底物复合物的 Kii 为 13 μM,而对人谷胱甘肽还原酶无显著抑制作用。
Kukoamine A (0.1 mM; 20-60 min) 表现出较强的 DPPH 自由基清除活性,在无细胞体系中孵育 20 min 和 60 min 后,0.1 mM 浓度下的还原活性均为 96%。
Kukoamine A 可强效抑制无细胞体系中的大豆脂氧合酶,其 IC50 为 9.5 μM。
Kukoamine A (0.1 mM) 可抑制 72% 的 AAPH 诱导亚油酸脂质过氧化反应。
Kukoamine A 可通过下调 Srebp-1c 逆转 AML-12 细胞中 palmitic acid 诱导的胰岛素抵抗、脂质蓄积和氧化应激,而 Srebp-1c 的过表达会消除这些保护作用。
Kukoamine A (10-80 μg/mL;作用 1-5 天) 以时间和剂量依赖的方式选择性抑制人胶质母细胞瘤 U251 和 WJ1 细胞的活力,在作用第 5 天时其 IC50 值分别为 73.4 μg/mL 和 22.1 μg/mL,而对人正常肝细胞 LO2 和大鼠胶质瘤 C6 细胞的影响极小。
Kukoamine A (5-20 μg/mL; 12 days) 以剂量依赖的方式抑制人胶质母细胞瘤 U251 和 WJ1 细胞的克隆形成能力。
Kukoamine A (10-80 μg/mL;48 h) 以剂量依赖方式诱导人胶质母细胞瘤 U251 和 WJ1 细胞发生凋亡,下调 5-LOX 和抗凋亡蛋白 Bcl-2 的表达,并上调促凋亡蛋白 Bax 和活化型 caspase-3 的表达。
Kukoamine A (5-20 μg/ml;48 h) 以剂量依赖的方式诱导人胶质母细胞瘤 U251 和 WJ1 细胞发生 G0/G1 期细胞周期阻滞。
Kukoamine A (10-80 μg/mL;24 h) 可呈剂量依赖性抑制人胶质母细胞瘤 U251 细胞和 WJ1 细胞的迁移和侵袭。
Kukoamine A (10-40 μM;预孵育 4 h,随后与 MPP+ 共孵育 24 h) 可呈剂量依赖性地保护 SH-SY5Y 细胞免受 MPP+ 诱导的损伤,抑制凋亡并维持线粒体膜电位。
Kukoamine A (10-40 μM;预孵育 4 h,随后与 MPP+共孵育 24 h) 在 SH-SY5Y 细胞中呈剂量依赖性地降低 Bax/Bcl-2 比率、p-JNK 和 p-p38 水平,并增加 p-AKT、p-ERK 水平。
Kukoamine A (10-40 μM;4 h) 可在 SH-SY5Y 细胞中呈剂量依赖性诱导自噬,在最高浓度下可诱导形成可见的自噬体,,增加 LC3-II/LC3-I 的比值、Beclin-1 的水平,并降低 p62 的水平。
Kukoamine A 可高亲和力结合 HEK293T 细胞膜上表达的人 μ 型阿片受体,其 Ki 值为 1.3 ± 0.18 μM,EC50 值为 5.6 ± 0.65 μM。
Kukoamine A (5-40 μM;24 h) 不会降低 RAW 264.7 巨噬细胞的存活率。
Kukoamine A (5-40 μM;24 h) 以浓度依赖的方式显著抑制 LPS (MS-X54539) 诱导的 RAW 264.7 巨噬细胞中 NO、ROS、PGE2、TNF-α、IL-1β 和 IL-6 的 的生成。
Kukoamine A (5-40 μM) 可显著抑制 LPS 诱导的 RAW 264.7 巨噬细胞中 COX-2 活性。

Apoptosis Analysis

Cell Line: human glioblastoma U251 cells, human glioblastoma WJ1 cells
Concentration: 40, 60, 80 μg/ml (U251 cells); 10, 20, 30 μg/ml (WJ1 cells)
Incubation Time: 48 h
Result:
Induced a significant, dose-dependent increase in both early and late apoptotic cells, as well as total apoptotic cells, in both U251 and WJ1 cells compared to untreated controls.

Cell Cycle Analysis

Cell Line: human glioblastoma U251 cells, human glioblastoma WJ1 cells
Concentration: 5, 10, 20 μg/ml
Incubation Time: 48 h
Result: Caused a significant, dose-dependent increase in the cell population in the G0/G1 phase in both U251 and WJ1 cells compared to untreated controls.
Caused a corresponding significant, dose-dependent decrease in the cell population in the S phase in both U251 and WJ1 cells compared to untreated controls.

Western Blot Analysis

Cell Line: human glioblastoma U251 cells, human glioblastoma WJ1 cells
Concentration: 40, 60, 80 μg/ml (U251 cells); 10, 20, 30 μg/ml (WJ1 cells)
Incubation Time: 48 h
Result: Caused a dose-dependent decrease in 5-LOX and Bcl-2 protein expression in U251 and WJ1 cells.
Caused a dose-dependent increase in Bax and active caspase-3 protein expression in U251 and WJ1 cells.
Caused a dose-dependent decrease in C/EBPβ, N-cadherin, vimentin, twist, and snail+slug protein expression in U251 and WJ1 cells.
Caused a dose-dependent increase in E-cadherin protein expression in U251 and WJ1 cells.

Western Blot Analysis

Cell Line: MPP⁺-treated SH-SY5Y human neuroblastoma cells
Concentration: 10 μM, 20 μM, 40 μM
Incubation Time: 4 h pre-incubation, followed by 24 h co-incubation with MPP⁺
Result: Decreased the Bax/Bcl-2 ratio to 3.77 ± 0.36, 2.22 ± 0.17, and 0.68 ± 0.31 at 10, 20, and 40 μM, respectively.
Increased p-AKT levels to 2.05 ± 0.07.
Increased p-ERK levels to 3.31 ± 0.14.
Decreased p-JNK levels to 0.57 ± 0.02.
Decreased p-p38 levels to 0.21 ± 0.06 compared to MPP⁺-treated cells.

ELISA Assay

Cell Line: LPS-stimulated RAW 264.7 macrophage cells
Concentration: 5, 10, 20, 40 μM
Incubation Time: 12 h (pretreatment); 12 h (LPS stimulation)
Result: Significantly attenuated LPS-induced increases in TNF-α, IL-1β, and IL-6 levels in a concentration-dependent manner, with all tested concentrations showing statistically significant inhibition relative to LPS-only treated cells.
Significantly reduced LPS-induced PGE2 levels, with all tested concentrations showing statistically significant inhibition relative to LPS-only treated cells.
Markedly inhibited LPS-induced COX-2 activity.
体内研究
(In Vivo)

Kukoamine A (0.01 mmol/kg;腹腔注射;单剂量) 可将 Carrageenan (MS-L60716) 诱导的大鼠足爪水肿抑制 43%。
Kukoamine A (5-20 mg/kg;腹腔注射;每日给药;持续 4 周) 可通过抑制 Srebp-1c 及其下游靶基因的表达,以剂量依赖的方式缓解小鼠中高脂饮食诱导的胰岛素抵抗、脂肪肝、炎症及氧化应激。
Kukoamine A (10-40 mg/kg;腹腔注射;每周 5 次;持续 4 周) 可呈剂量依赖性抑制胶质母细胞瘤的体内生长,在 40 mg/kg 剂量下肿瘤抑制率最高可达 55.3%,同时不会降低小鼠体重;其作用机制为通过下调 5-LOX 和 C/EBPβ 的表达,诱导细胞凋亡并减弱上皮-间质转化。
Kukoamine A (5-20 mg/kg;灌胃;每日给药,连续 12 天) 通过改善运动功能、减少神经元凋亡、降低 α-突触核蛋白水平、保留多巴胺能神经元并增强自噬的方式,在 MPTP (MS-O89430) 诱导的帕金森病小鼠模型中发挥剂量依赖性神经保护作用,且不影响 MAO-B 活性。
Kukoamine A (5-20 mg/kg;灌胃;每日给药,连续 12 天) 可通过调控自噬相关蛋白增强健康小鼠黑质 (SN) 和纹状体 (Str) 中的自噬水平,且不会诱导细胞凋亡或改变 MAO-B 活性。
Kukoamine A (25-50 mg/kg;口服;每日给药,连续 5 天) 对 Carrageenan (MS-L60716) 诱导急性炎症的大鼠具有浓度依赖性抗炎与抗氧化作用,可减轻足爪肿胀、降低促炎细胞因子水平及氧化应激标志物水平,同时提升肝脏抗氧化酶活性。

Animal Model: Carrageenan-induced edema Fischer-344 rats (male and female, 150-200 g, non-pregnant females; 6-15 animals per group)
Dosage: 0.01 mmol/kg
Administration: I.p.; single dose
Result: Inhibited carrageenan-induced rat paw edema by 43%.
Animal Model: C57 (6-8 weeks old; high fat diet-induced model)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: I.p.; daily; 4 weeks
Result: Dose-dependently inhibited HFD-induced increases in fasting blood glucose and insulin levels, and dose-dependently reduced glucose levels in response to glucose and insulin loads during IPGTT and IPITT.
Dose-dependently decreased HFD-induced liver histological injury, hepatic triglyceride levels, and serum AST and ALT activities.
Dose-dependently inhibited HFD-induced increases in serum TNFα, IL-1β, IL-6, and C reactive protein levels.
Dose-dependently reversed HFD-induced reductions in hepatic MnSOD and CuZnSOD activities, and dose-dependently inhibited HFD-induced increases in hepatic MDA and H2O2 levels.
Dose-dependently inhibited HFD-induced upregulation of hepatic Srebp-1c protein and mRNA expression, as well as hepatic mRNA expression of the Srebp-1c target genes FAS and ACC1.
Animal Model: BALB/C-nu/nu nude mice (5-week-old, male, intraperitoneal inoculation of human GBM WJ1 cells)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: I.p.; 5 times weekly; 4 weeks
Result: Reduced mean tumor weight.
Achieved tumor inhibitory rates of 35.2%, 48.8%, and 55.3% at 10, 20, and 40 mg/kg doses, respectively.
Showed no difference in body weight increase compared to control mice.
Significantly decreased 5-LOX, Bcl-2, C/EBPβ, N-cadherin, vimentin, twist, and snail+slug protein expression in tumor tissues in a dose-dependent manner.
Significantly increased Bax, active caspase-3, and E-cadherin protein expression in tumor tissues in a dose-dependent manner.
Animal Model: C57BL/6 (male, 7~8 weeks old, 20~22 g, MPTP-induced modeling)
Dosage: 5 mg/kg; 20 mg/kg
Administration: I.g.; daily; 12 days
Result: Increased the time mice stayed on the rota-rod, reduced the time to climb down the pole, and increased traction test scores at all tested time points compared to MPTP-only mice.
Increased the level of Nissl substance in the substantia nigra (SN), reversed the MPTP-induced increase in Bax and cytochrome c expression, reversed the decrease in Bcl-2 expression, and reduced caspase-3 activity in both SN and striatum (Str) in a dose-dependent manner.
Decreased MPTP-induced α-synuclein elevation in SN and Str, attenuated MPTP-induced loss of tyrosine hydroxylase (TH)-positive cells in SN and Str, and attenuated MPTP-induced reduction in TH protein levels in SN and Str.
Upregulated the LC3-II/LC3-I ratio and Beclin-1 expression, and downregulated p62 expression in both SN and Str.\nDid not alter MAO-B activity in the brain.
Animal Model: Carrageenan-induced Wistar rats (male, 180-220 g)
Dosage: 25 mg/kg; 50 mg/kg
Administration: P.o.; daily; 5 days
Result: Significantly reduced carrageenan-induced paw edema volume in a concentration-dependent manner over the 4-hour observation period.
Significantly reduced serum levels of proinflammatory cytokines TNF-α, IL-1β, and IL-6.
Significantly increased liver activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px).
Significantly reduced liver malondialdehyde (MDA) levels.\nAll results were statistically significant.
性状 固体
颜色 White to off-white

化学信息

分子量 530.66
分子式 C28H42N4O6
CAS No. 75288-96-9
别名 地骨皮甲素

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.77 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 125 mg/mL (235.56 mM; 超声助溶)

DMSO 中的溶解度 : 100 mg/mL (188.44 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM1.8844 mL9.4222 mL18.8445 mL47.1111 mL
5 mM0.3769 mL1.8844 mL3.7689 mL9.4222 mL
10 mM0.1884 mL0.9422 mL1.8844 mL4.7111 mL
15 mM0.1256 mL0.6281 mL1.2563 mL3.1407 mL
20 mM0.0942 mL0.4711 mL0.9422 mL2.3556 mL
25 mM0.0754 mL0.3769 mL0.7538 mL1.8844 mL
30 mM0.0628 mL0.3141 mL0.6281 mL1.5704 mL
40 mM0.0471 mL0.2356 mL0.4711 mL1.1778 mL
50 mM0.0377 mL0.1884 mL0.3769 mL0.9422 mL
60 mM0.0314 mL0.1570 mL0.3141 mL0.7852 mL
80 mM0.0236 mL0.1178 mL0.2356 mL0.5889 mL
100 mM0.0188 mL0.0942 mL0.1884 mL0.4711 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

地骨皮甲素 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础